Latest medullary thyroid cancer Stories
LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001).
Individuals with papillary thyroid cancer that has not spread beyond the thyroid gland appear to have favorable outcomes regardless of whether they receive treatment within the first year after diagnosis.
People living in volcanic areas may be at a higher risk for thyroid cancer, according to a new study published online November 5 in the Journal of the National Cancer Institute.
In a study of patients undergoing thyroid surgery performed by a single surgeon, older adults did not appear to have more complications than younger patients, according to a report in October issue of Archives of Otolaryngologyâ€“Head & Neck Surgery, one of the JAMA/Archives journals.
Using a novel robot-assisted endoscopic technique, a team of surgeons at Yonsei University College of Medicine in Seoul, Korea, has successfully treated 200 consecutive patients with thyroid cancer.
New guidelines designed to standardize and optimize the diagnosis, treatment, and monitoring of patients with Medullary Thyroid Carcinoma (MTC), an uncommon and challenging form of thyroid cancer, have been developed by the American Thyroid Association and published online ahead of print in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc.
Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844.
By Zaydfudim, Victor Stover, Daniel G; Caro, Susan W; Phay, John E Although medullary thyroid cancer (MTC) can produce adrenocorticotropic hormone (ACTH) in up to 40 per cent of cases as determined by immunohistochemistry, clinical hypercortisolism is rarely seen.
Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to GSK.
San Francisco-based biotech Exelixis has seen its shares rise after taking an investigational thyroid cancer drug into a Phase III trial.
- A gift; a largess; a gratuity; a present; a dole.